Slingshot members are tracking this event:

Celgene (CELG) Phase III data readout of RELEVANCE trial testing Revlimid in previously untreated follicular lymphoma expected by end of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
CELG Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 21, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Results, Relevance, Indolent Non-hodgkin Lymphoma, Revlimid